# Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

> **NCT07171203** · PHASE1 · RECRUITING · sponsor: **University of California, San Diego** · enrollment: 18 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Fampridine

## Key facts

- **NCT ID:** NCT07171203
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2030-07
- **Final completion:** 2031-07
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07171203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07171203, "Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07171203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*